Sponsored

Cynata’s (ASX:CYP) proposed aGvHD phase 2 clinical trial gets IRB approval - Kalkine Media

February 01, 2023 11:56 AM AEDT | By Aditi Sarkar
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

Highlights

  • Cynata has secured Institutional Research Board (IRB) approval to start the proposed acute graft versus-host disease (aGvHD) phase 2 clinical trial in the US.
  • The approval was granted by Advarra, Inc., a central IRB (i.e. ethics committee) service provider in the USA.
  • IRB approval is an essential step in the process of opening clinical study sites and commencing a clinical trial in humans in the United States.
  • As per the company, the new study will be based on the excellent results achieved in phase 1 clinical trial of CYP-001, in which all safety and efficacy endpoints were met.

Cynata Therapeutics (ASX:CYP) has marked a major development, securing IRB approval to start the proposed phase 2 clinical trial in aGvHD in the United States. The approval has been granted by Advarra, Inc., a central Institutional Research IRB service provider in the US.

Cynata is an ASX-listed clinical-stage stem cell and regenerative medicine company. Based on its patented therapeutic stem cell platform technology Cymerus™, the company is committed to developing therapies for unmet medical needs. CYP-001, the lead product candidate of Cynata, is undergoing clinical development for  aGvHD.

IRB approval for proposed aGvHD phase 2 clinical trial

Securing IRB approval is a critical step in the process of opening clinical study sites and commencing a clinical trial in humans in the United States.

Cynata is now concluding contractual and logistic procedures with individual sites (hospitals) to arrange for patient recruitment. The development follows the milestone clearance of Cynata’s Investigational New Drug (IND) application in 2022 and grant of Orphan Drug Status for CYP-001, as well as very promising results from a Phase 1 clinical trial.

Commenting on the progress, Dr Jolanta Airey, Cynata’s Chief Medical Officer, said:

© 2023 Krish Capital Pty. Ltd., Data and image source: Company update

Meeting all clinical endpoints, CYP-001 indicated positive safety and efficacy data for the treatment of steroid-resistant aGvHD in the Phase 1 trial.

Overview of the Proposed Trial

The title of the proposed clinical trial is “A Multicenter, Randomized, Double-blind, Placebo-Controlled Phase 2 Study to Investigate the Efficacy and Safety of CYP-001 in Combination with Corticosteroids vs Corticosteroids Alone for the Treatment of High-Risk Acute Graft Versus Host Disease”. It is anticipated to be carried out in nearly 60 patients at sites in Australia, Europe, and the United States.

Besides this milestone achievement in the United States, Cynata is making progress in Europe and Australia, Dr Airey highlighted. The company anticipates starting patient recruitment in the coming few months and aims to complete the initial evaluation of the trial data in 2024.

CYP shares were trading at AU$0.33 midday on 1 February 2023.


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (Kalkine Media, we or us), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

5 ASX Companies Leveraging AI to Drive Growth in 2024



Top ASX Listed Companies


We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.